ASCO 2015: Highlights in Multiple Myeloma
Release Date: June 12, 2015
Expiration Date: June 12, 2016
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
Multiple myeloma (MM), a plasma cell dyscrasia characterized by clonal proliferation of plasma cells in the bone marrow microenvironment which, if left untreated, leads to CRAB symptoms and subsequent end organ damage. Multiple myeloma may challenge community oncology physicians, nurses, and pharmacists as it is a small incidence cancer with which they have little experience managing; as few as 26,850 new cases are anticipated to be diagnosed in the United States in 2015. Fortunately, rapid translation of clinical insights and new treatments from bench to bedside have remarkably altered the natural progression of this hematologic malignancy in community practice. Since the introduction of a proteasome inhibitor and IMiDs with or without high-dose chemotherapy with alkylator and autologous stem cell transplant support, overall survival for MM has nearly doubled. With the FDA approval of an unprecedented number of new agents in the past 15 years, survival has continued to improve, even in elderly patients. Rapid progress, which includes not just the continued clinical development and introduction of new and highly active therapies but also more effective side-effect management and improved supportive care strategies, has led to a paradigm shift in which the course of MM is now more characteristic of a chronic disease to be managed rather than a nearly universally lethal malignancy that it once was. Challenges do remain. Most patients eventually relapse, and while the majority of these patients have benefited by achieving significantly prolonged survival, some patients, as observed retrospectively, still present with disease that is highly resistant to all currently available therapeutic options. Fortunately, insights into the clonal evolution of MM and the underlying biologic characteristics of clonal heterogenicity have provided new avenues of clinical exploration and development. It is therefore essential that community practitioners remain current with these continuing advances as reported at national society meetings so they are prepared to rapidly and appropriately translate these advances into practice according to individual patient needs.
Join our Managing Myeloma team world-leading experts including Drs. Meletios Dimopoulos, Sagar Lonial, Donna Reece, and Edward Stadtmauer live from the 2015 annual meeting of the American Society of Clinical Oncology in Chicago as each discusses a number of the most significant clinical presentations addressing multiple myeloma management, and the potential impact these new findings will have on community practice, both today as well as in the near future.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Recall efficacy and safety outcomes of new and emerging agents, regimens, and management strategies for multiple myeloma as reported at the 2015 ASCO annual meeting, as well as any study limitations that may affect interpretation of those findings
- Relate how recent clinical findings for multiple myeloma treatment and management, as reported at the 2015 ASCO annual meeting, will either immediately impact current practice or potentially do so in the near future
ASCO 2015: Highlights in Multiple Myeloma
Updates from the FIRST Trial Further Support Continuous Therapy in Newly Diagnosed, Non-Transplant Patients, The ASPIRE Trial (KRD vs RD) and Twin Randomized Studies of Daratumumab in Relapsed/Refractory Disease – Meletios A. Dimopoulos, MD
Updates and New Approaches to Relapsed Refractory Disease: The ENDEAVOR Trial Head to Head Comparison of KD and VD; Targeting SLAMF7, Kinesin Spindle Protein, and HDACs – Sagar Lonial, MD
Advances in Newly Diagnosed Multiple Myeloma – Donna E. Reece, MD
An Overview for Multiple Myeloma with Updates on Pomalidomide Regimens in R/R Disease and a New Investigational Hypoxia-activated Prodrug – Edward A. Stadtmauer, MD
Instructions for Participation and Credit
This activity is eligible for credit through June 12, 2016. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Meletios A. Dimopoulos, MD
Professor and Chairman
Department of Clinical Therapeutics
National and Kapodistrian University of Athens School of Medicine
Dr. Meletios Dimopoulos received his medical degree from the National and Kapodistrian University of Athens, Greece. He completed a residency in internal medicine at the Royal Victoria Hospital, McGill University, Montreal, Canada, and a fellowship in hematology/oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas. Dr. Dimopoulos is professor and chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine; he was also elected dean of the medical school and rector of the university.
Dr. Dimopoulos serves on the scientific advisory boards of the International Myeloma Foundation and the International Waldenström’s Macroglobulinemia Foundation, and is a board member of the European Myeloma Network and the International Myeloma Society. He has authored more than 700 publications in peer-reviewed journals, as well as numerous abstracts and several textbook chapters primarily focusing on plasma cell dyscrasias, and genitourinary and gynecologic cancers. In addition, Dr. Dimopoulos is a journal reviewer for The New England Journal of Medicine, Blood, Haematologica, Leukemia, Cancer, European Journal of Haematology, and Leukemia and Lymphoma. He is also associate editor of Current Hematologic Malignancy Reports, and is an editorial board member of Haematologica, Leukemia and Lymphoma, Clinical Lymphoma and Myeloma, and Expert Review of Hematology.
Sagar Lonial, MD
Vice Chair of Clinical Affairs
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Dr. Sagar Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology/oncology at Emory University School of Medicine in Atlanta, Georgia. He is a professor in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University where he is also the vice chair of clinical affairs, as well as director of the Translational Research for the B-Cell Malignancy Program.
He is involved in numerous professional organizations including the American Society of Clinical Oncology, American Society of Hematology, and the American Society for Blood and Marrow Transplantation. In addition, he serves on the editorial board of the Journal of Clinical Oncology, Leukemia, and is the myeloma editor for Clinical Lymphoma, Myeloma, and Leukemia, and also serves as an invited and ad hoc reviewer for several publications including Blood, Haematologica, Clinical Cancer Research, The New England Journal of Medicine, and others. Dr. Lonial has authored/coauthored over 200 publications and recently was awarded the Celgene ‘Young Investigator’ Award, the MMRF ‘Top 15 Innovator’ Award, and the MMRC ‘Center of the Year’ award.
Dr. Lonial’s research interest is on combination therapy in B-cell malignancies focusing on myeloma. He is a trained bone marrow transplant physician with an interest in molecular therapy for lymphoma and myeloma. His clinical interests include evaluating the combination of new molecular targeted agents for B-cell tumors as well as target discovery and validation.
Donna Reece, MD
Director, Program for Multiple Myeloma and Related Diseases
Department of Medical Oncology and Hematology
Princess Margaret Hospital
University of Toronto
Dr. Donna Reece received her medical degree from Baylor College of Medicine, Houston, Texas. She completed an internship in internal medicine at the University of Colorado Affiliated Hospitals, a residency and chief residency in internal medicine at Jewish Hospital, St. Louis, and a fellowship in hematology/oncology at Barnes Hospital, Washington University, St. Louis. She was a fellow and later a leukemia/stem cell transplant physician at Vancouver General Hospital/University of British Columbia. Currently, Dr. Reece is associate professor and director of the Program for Multiple Myeloma and Related Diseases in the Department of Medical Oncology and Hematology at Princess Margaret Hospital/University of Toronto.
Dr. Reece has served as director of the Outpatient Leukemia/Stem Cell Transplant Program and interim director of the Blood and Marrow Transplant Program of the Markey Cancer Center at the University of Kentucky, Lexington. She is currently chair of the Multiple Myeloma Clinical Trials Group of the National Cancer Institute of Canada, co-chair of the Myeloma Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), as well as a member of the Scientific Advisory Board of the International Myeloma Foundation and the Project Review Committee of the MMRC (Multiple Myeloma Research Consortium). Her career focus has been in the areas of hematopoietic stem cell transplantation, lymphoid malignancies, and plasma cell dyscrasias. She has published numerous articles in these areas.
Edward A. Stadtmauer, MD
Chief, Hematologic Malignancies
Abramson Cancer Center
University of Pennsylvania
Dr. Edward Stadtmauer completed his medical degree at the University of Pennsylvania School of Medicine, and served his internship and residency in internal medicine at Albert Einstein College of Medicine, Bronx, New York. He completed his fellowship in hematology-oncology at the University of Pennsylvania where he is currently chief of the Hematologic Malignancies Section of the Abramson Cancer Center.
Board certified in internal medicine, hematology, and medical oncology, Dr. Stadtmauer is a reviewer for numerous journals and is on the editorial board of the Journal of Clinical Oncology. He is widely published on the subjects of acute and chronic leukemia, autologous bone marrow transplantation, and multiple myeloma. Dr. Stadtmauer’s writings have appeared in peer-reviewed journals such as Annals of Internal Medicine, Blood, Bone Marrow Transplantation, Journal of Clinical Oncology, and The New England Journal of Medicine, among others.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-15-043-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 15-043-013
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Meletios Dimopoulos has received honoraria as a consultant from Celgene Corporation, Janssen Pharmaceuticals, Inc., and Onyx. He has received grant support related to research activities from Amgen Inc., GENESIS Pharma S.A., and Janssen.
Dr. Sagar Lonial has received honoraria as a consultant from Bristol-Myers Squibb, Celgene Corporation, Novartis AG, Onyx, Sanofi, and Takeda Oncology.
Dr. Donna Reece has received honoraria related to formal advisory activities from Celgene Corporation, Onyx, and Janssen Pharmaceuticals, Inc., as well as speakers’ bureau activities from Janssen, Celgene, and Novartis AG. She has received grant support related to research activities from Bristol-Myers Squibb, Celgene, Merck & Co., Inc., Takeda Oncology, and Otsuka Pharmaceutical Co., Ltd.
Dr. Edward Stadtmauer has received honoraria as a consultant from Novartis AG, Onyx, Sanofi, and Takeda Oncology. He has received grant support related to research activities from Celgene Corporation, Novartis, and Onyx.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Dimopoulos has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Dimopoulos has indicated that he does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US
Dr. Lonial has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Lonial has indicated that he does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
Dr. Reece has indicated that she does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Reece has indicated that she does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
Dr. Stadtmauer has indicated that he does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Stadtmauer has indicated that he does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Takeda Oncology and Celgene Corporation.
©2015 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.